Advertisement
Advertisement
ARQT
Arcutis Biotherapeutics, Inc. Common Stock
25.38
USDSponsored
-0.35
-1.37%
Jan 30, 16:00 UTC -5
Closed
After-Market
25.37
-0.01
-0.03%
ARQT Earnings Reports
Positive Surprise Ratio
ARQT beat 20 of 24 last estimates.
83%
Next Report
Date of Next Report
Feb 25, 2026
Estimate for Q4 25 (Revenue/ EPS)
$114.00M
/$0.07
Implied change from Q3 25 (Revenue/ EPS)
+14.90%
/+16.67%
Implied change from Q4 24 (Revenue/ EPS)
+59.76%
/-177.78%
Arcutis Biotherapeutics, Inc. Common Stock earnings per share and revenue
On Oct 28, 2025, ARQT reported earnings of 0.06 USD per share (EPS) for Q3 25, beating the estimate of -0.10 USD, resulting in a 158.88% surprise. Revenue reached 99.22 million, compared to an expected 88.72 million, with a 11.84% difference. The market reacted with a +27.04% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 10 analysts forecast an EPS of 0.07 USD, with revenue projected to reach 114.00 million USD, implying an increase of 16.67% EPS, and increase of 14.90% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Regeneron Pharmaceuticals Inc
Report Date
Jan 30, 2026 For Q4 25
Estimate
$10.84
Actual
$11.44
Surprise
+5.52%
Nurix Therapeutics, Inc. Common stock
Report Date
Jan 28, 2026 For Q4 25
Estimate
-$0.88
Actual
-$0.82
Surprise
+7.66%
FAQ
What were Arcutis Biotherapeutics, Inc. Common Stock's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, Arcutis Biotherapeutics, Inc. Common Stock reported EPS of $0.06, beating estimates by 158.88%, and revenue of $99.22M, 11.84% above expectations.
How did the market react to Arcutis Biotherapeutics, Inc. Common Stock's Q3 2025 earnings?
The stock price moved up 27.04%, changed from $19.64 before the earnings release to $24.95 the day after.
When is Arcutis Biotherapeutics, Inc. Common Stock expected to report next?
The next earning report is scheduled for Feb 25, 2026.
What are the forecasts for Arcutis Biotherapeutics, Inc. Common Stock's next earnings report?
Based on 10
analysts, Arcutis Biotherapeutics, Inc. Common Stock is expected to report EPS of $0.07 and revenue of $114.00M for Q4 2025.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement